Per Rehne of Optibiotix Health (LON:OPTI) tells Proactive how the company's commercial journey through clinical trails, manufacturing and ultimately selling is a careful process of which he's been perfecting since he joined nine months ago. OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. Expanding the worldwide Optibiotix project portfolio is now the focus...hear how Per and the team intend to do just that.
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »